We herewith submit unaudited financial result for the quarter and nine months ended on 31st December, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Link Pharma Chem Ltd reported Q3 FY26 revenue of Rs 673.47 lakhs, up about 26% year-on-year from Rs 534.24 lakhs. Nine-month revenue grew to Rs 2,084.27 lakhs from Rs 1,898.68 lakhs, with the company single-handedly into the manufacture and sale of chemicals. Profit for Q3 came in at Rs 6.82 lakhs versus a loss of Rs 66.71 lakhs in the same quarter last year. Nine-month profit stood at Rs 48.55 lakhs compared to a loss of Rs 67.71 lakhs in 9M FY25, marking a clear turnaround. Basic EPS for Q3 was Rs 0.15, against a loss of Rs 1.50 in Q3 FY24. The auditor (CNK & Associates LLP) issued a clean limited review report with no qualifications.
Strong year-on-year revenue growth and a return to profitability are positive signals for shareholders, suggesting improving operating performance despite a fair-value loss on investments dragging down other income. The clean auditor report and absence of any flags strengthen investor confidence.